Lim Ee Tuan, Giovannoni Gavin
University College London, Department of Neuroinflammation, Institute of Neurology, Queen Square, London, WC1N 3BG, UK.
Expert Rev Neurother. 2005 May;5(3):379-90. doi: 10.1586/14737175.5.3.379.
Multiple sclerosis is an organ-specific autoimmune disease, characterized pathologically by cell-mediated inflammation, demyelination and variable degrees of axonal loss. Although inflammation is considered central to the pathogenesis of multiple sclerosis, to date, the only licensed and hence widely used multiple sclerosis immunotherapies are interferon-beta, glatiramer acetate and mitoxantrone. This review discusses the immunopathogenesis of multiple sclerosis, focusing on a number of emerging immunotherapies. A number of new approaches likely to manipulate the immunopathogenesis of multiple sclerosis and which may ultimately allow for the development of more effective immunotherapy are also highlighted.
多发性硬化症是一种器官特异性自身免疫性疾病，其病理特征为细胞介导的炎症、脱髓鞘以及不同程度的轴突损失。尽管炎症被认为是多发性硬化症发病机制的核心，但迄今为止，唯一获得许可并因此广泛使用的多发性硬化症免疫疗法是β-干扰素、醋酸格拉替雷和米托蒽醌。本综述讨论了多发性硬化症的免疫发病机制，重点关注一些新兴的免疫疗法。还强调了一些可能操纵多发性硬化症免疫发病机制并最终可能促成更有效免疫疗法发展的新方法。
